Last reviewed · How we verify

Articaine hydrochloride 2% solution

Helsinki University Central Hospital · FDA-approved active Small molecule

Articaine hydrochloride is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Articaine hydrochloride is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses. Used for Local and regional anesthesia for dental procedures, Infiltration anesthesia, Nerve block anesthesia.

At a glance

Generic nameArticaine hydrochloride 2% solution
Also known asUltracain D ohne Adrenalin 20 mg/ml, ATC code N01BB08
SponsorHelsinki University Central Hospital
Drug classLocal anesthetic (amide type)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Articaine is an amide-type local anesthetic that reversibly inhibits sodium influx into nerve fibers, thereby preventing depolarization and action potential generation. This results in loss of sensation in the infiltrated tissue. Articaine is metabolized by plasma esterases and hepatic enzymes, with a relatively rapid onset and intermediate duration of action compared to other local anesthetics.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: